IDEXX Laboratories, Inc.
IDXX
$509.56
+0.96%
IDEXX Laboratories develops, manufactures, and distributes diagnostic products, equipment, and services for companion animals and livestock, spanning in-clinic single-use test kits, benchtop chemistry and hematology analyzers, reference laboratory services, and veterinary practice management software, with roughly 35% of revenue generated outside the United States. The company is the dominant global platform in veterinary diagnostics, enjoying razor-and-blade economics where instrument placements drive high-margin consumable and reference-lab revenue, a position reinforced by deep relationships with veterinary practices and a software layer that competitors have struggled to replicate. The current investor debate centers on whether IDEXX can sustain its premium growth algorithm as U.S. veterinary clinic visit growth normalizes, with the bulls pointing to the Q1 2026 revenue acceleration and management's raised long-term guidance on higher clinical visits and diagnostic frequency, while bears highlight the stock's severe underperformance, decelerating companion-animal utilization, and the risk that elevated valuation multiples compress further. With the shares down sharply year-to-date and trading near 52-week lows despite solid fundamental execution, the narrative has shifted from a growth-at-any-price compounder to a debate about whether the market has over-discounted a durable franchise.…
IDXX
IDEXX Laboratories, Inc.
$509.56
Related headlines
Investment Opinion: Should I buy IDXX Today?
The synthesized recommendation is Hold with a bullish bias. The core thesis is that IDEXX remains a high-quality compounder with 14.26% revenue growth, expanding margins, and a forward PE of 30.15x that is near multi-year lows, but the severe negative momentum and -37.99% relative underperformance versus SPY over one year warrant caution until the stock stabilizes. The analyst consensus rating is Buy with a recommendation mean of 2.21, and the average target price of $698.92 implies +38.5% upside, anchoring a constructive medium-term view.
Supporting evidence for the Hold rating includes: (1) revenue growth of 14.26% year-over-year in Q1 2026, accelerating from the prior-year comparison; (2) gross margin expansion to 63.35% from 60.35% in Q4 2025, with net margin rising to 24.41%; (3) free cash flow of $1.08 billion TTM and $351.0 million of stock repurchased in Q1 2026; and (4) a forward PE of 30.15x versus a trailing PE of 51.37x, implying a significant earnings step-up that, if delivered, would make the stock look inexpensive. The PEG ratio of 2.31, however, indicates the growth premium is still substantial.
The biggest risks that could invalidate the thesis are: (1) a decisive break below the 52-week low of $500.61, which would likely trigger momentum-driven selling; (2) deceleration in U.S. veterinary clinic visit growth below management's raised guidance; and (3) further multiple compression if the forward EPS estimate of $25.62 is revised downward. This Hold would upgrade to Buy if the stock stabilizes above $520 and Q2 2026 revenue growth exceeds 14%, or downgrade to Sell if revenue growth decelerates below 10% or the stock breaks below $500 on high volume. Relative to its history, the stock is undervalued on a forward basis but still carries a premium on absolute metrics like EV/EBITDA of 37.50x.
Sign up to view all
IDXX 12-Month Price Forecast
IDEXX presents a classic quality-versus-momentum dilemma. The fundamental case is strong: 14.26% revenue growth, expanding margins, robust free cash flow of $1.08 billion TTM, and a forward PE of 30.15x that is near multi-year lows. However, the technical picture is deeply bearish, with the stock at 1.5% of its 52-week range, accelerating downside momentum, and persistent institutional distribution. The market is pricing a materially more bearish scenario than the sell-side, creating a potential disconnect that could resolve violently in either direction. I would upgrade to bullish if the stock stabilizes above $520 and Q2 2026 revenue growth exceeds 14%, or downgrade to bearish if the stock breaks below $500 on high volume or if revenue growth decelerates below 10%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on IDEXX Laboratories, Inc.'s 12-month outlook, with a consensus price target around $698.92 and implied upside of +37.2% versus the current price.
Average Target
$698.92
0 analysts
Implied Upside
+37.2%
vs. current price
Analyst Count
—
covering this stock
Price Range
$470 - $805
Analyst target range
Coverage is solid with 13 analysts, and the consensus recommendation is Buy with a recommendation mean of 2.21 (where lower is more bullish), indicating a moderately bullish tilt. The average target price is $698.92, which implies roughly +38.5% upside from the current price of $504.70 — a strikingly wide gap that reflects either significant undervaluation or stale targets that have not yet been revised downward to reflect the recent collapse. The consensus EPS estimate of $25.62 (range $25.33 to $25.94) and revenue estimate of $6.93 billion (range $6.87 billion to $7.00 billion) suggest analysts expect continued double-digit growth, and the tightness of the EPS and revenue estimate ranges indicates high confidence in the near-term fundamental trajectory even as the stock price dislocates. The bullish consensus is notable given the stock's -21.77% one-year decline, implying that the sell-side views the weakness as a valuation reset rather than a fundamental breakdown. The target range is extremely wide — from a low of $470.00 to a high of $805.00, a spread of $335 or roughly 71% of the low target — which signals unusually high uncertainty about the company's trajectory. The high target of $805.00 implies a return to near the 52-week high and would require both multiple expansion back toward historical norms and confidence that the 14%+ revenue growth and margin expansion continue; the low target of $470.00, which is below the current price, prices in further multiple compression, slowing veterinary visit growth, and possibly competitive or macroeconomic headwinds. Institutional ratings show a stable but mixed picture: recent actions include UBS maintaining Neutral (April 2026), Stifel maintaining Buy (March 2026), Piper Sandler maintaining Neutral (February 2026), Barclays maintaining Overweight, and BTIG maintaining Buy, with no upgrades or downgrades in the recent record — a pattern of entrenched positioning rather than active re-rating. The wide target spread combined with the stock trading near its 52-week low and the average target implying 38.5% upside suggests the market is pricing a materially more bearish scenario than the sell-side, creating a potential disconnect that could resolve violently in either direction.
Drowning in data?
Find the real signal!
Bulls vs Bears: IDXX Investment Factors
The bear case currently has stronger near-term evidence, with the stock at 1.5% of its 52-week range, accelerating downside momentum, and -37.99% relative strength versus SPY over one year. However, the bull case is grounded in hard fundamental data: 14.26% revenue growth, expanding gross margins to 63.35%, and a forward PE of 30.15x that is near multi-year lows. The single most important tension is whether the market is correctly pricing a structural deceleration in U.S. veterinary clinic visit growth or over-discounting a durable franchise with razor-and-blade economics. If Q2 2026 results confirm continued double-digit revenue growth and margin expansion, the stock could re-rate sharply toward analyst targets; if visit growth stalls, the multiple could compress further toward the bear-case target of $470.
Bullish
- Revenue growth accelerating, not decelerating: Q1 2026 revenue of $1.141 billion grew 14.26% year-over-year versus Q1 2025's $998.4 million, an acceleration from the prior-year comparison and the strongest recent print. The sequential trend is also constructive, with revenue rising from $1.091 billion in Q4 2025 to $1.105 billion in Q3 2025 to $1.141 billion in Q1 2026. This directly contradicts the bear narrative that companion-animal utilization is structurally rolling over.
- Margins expanding despite the selloff: Gross margin improved from 60.35% in Q4 2025 and 61.83% in Q3 2025 to 63.35% in Q1 2026, while net margin rose from 22.76% to 24.41% over the same span. EBITDA of $400.9 million in Q1 2026 (35.14% EBITDA margin) versus $356.2 million in Q4 2025 confirms operating leverage is working. A company with expanding margins is not experiencing fundamental deterioration.
- Analyst targets imply 38.5% upside: The average analyst target price of $698.92 implies roughly +38.5% upside from the current price of $504.70, with 13 analysts carrying a consensus Buy rating (recommendation mean of 2.21). The tightness of the EPS estimate range ($25.33 to $25.94) and revenue estimate range ($6.87 billion to $7.00 billion) indicates high confidence in the near-term fundamental trajectory even as the stock price dislocates.
- Valuation has compressed dramatically: The PS ratio has fallen from 69.72x in Q4 2021 to 12.59x today, a roughly 82% compression in the sales multiple, while the PE has fallen from 85.74x in Q4 2021 to 51.37x trailing and just 30.15x forward. The forward PE of 30.15x versus trailing 51.37x implies the market expects a dramatic earnings step-up, consistent with the consensus EPS estimate of $25.62. The stock is trading near the lower end of its multi-year valuation band.
Bearish
- Severe relative underperformance and downtrend: The stock is down -21.77% over one year and -24.67% YTD, versus the S&P 500's +16.22% and +12.08% gains over the same periods. Relative strength versus SPY is deeply negative across every window: -10.49% over 1 month, -13.06% over 3 months, and -37.99% over 1 year. This persistent institutional distribution is a powerful signal that the market sees something the sell-side does not.
- Trading at 1.5% of 52-week range: At $504.70, the stock sits just 1.5% above its 52-week low of $500.61 and roughly 34.5% below its 52-week high of $769.98, placing it at approximately 1.5% of its 52-week range. The maximum drawdown of -34.17% confirms the severity of the de-rating. A decisive break below $500.61 would open the door to further downside and likely trigger momentum-driven selling.
- Momentum is accelerating to the downside: The 1-month change of -11.55% is far worse than the 3-month change of -10.02% and the 6-month change of -12.05%, indicating that selling pressure is accelerating rather than stabilizing. The most recent sessions show a steady bleed from $556.69 on August 31 to $504.70 on September 11, a nearly uninterrupted nine-session slide. The absence of any bounce attempt argues against calling a bottom prematurely.
- Valuation still rich on absolute basis: Despite the derating, the EV/EBITDA of 37.50x and P/B of 33.75x are unambiguously rich on an absolute basis, and the PEG ratio of 2.31 indicates investors are still paying a meaningful premium for growth. The forward multiple is only attractive if the expected earnings step-up materializes. If growth decelerates, there is substantial room for further multiple compression.
IDXX Technical Analysis
IDEXX is in a sustained downtrend, with the shares at $504.70 after a 1-year decline of -21.77% and a year-to-date drop of -24.67%, a stark divergence from the S&P 500's +16.22% 1-year and +12.08% YTD gains. The stock is trading at just 1.5% above its 52-week low of $500.61 and roughly 34.5% below its 52-week high of $769.98, meaning it sits at approximately 1.5% of its 52-week range — a position that signals capitulation-style weakness rather than a value cushion, and one that historically precedes either a base-building recovery or further breakdown. The maximum drawdown of -34.17% confirms the severity of the de-rating, and with the price pressing against the low, the burden of proof is on buyers to defend this level. Recent momentum has deteriorated sharply: the 1-month change of -11.55% is far worse than the 3-month change of -10.02% and the 6-month change of -12.05%, indicating that selling pressure is accelerating rather than stabilizing. Relative strength versus SPY is deeply negative across every window — -10.49% over 1 month, -13.06% over 3 months, and -37.99% over 1 year — confirming persistent institutional distribution, while the most recent sessions show a steady bleed from $556.69 on August 31 to $504.70 on September 11, a nearly uninterrupted nine-session slide. With no RSI provided, the magnitude and consistency of the decline suggest oversold conditions may be developing, but the absence of any bounce attempt argues against calling a bottom prematurely. Key support sits at the 52-week low of $500.61, and a decisive break below that level would open the door to further downside and likely trigger momentum-driven selling; resistance is defined by the 52-week high of $769.98, with intermediate resistance around the $550-$570 zone where the stock repeatedly failed in August. The beta of 1.538 means IDEXX is roughly 54% more volatile than the market, so a 10% SPY drawdown could translate to a 15%+ move in IDXX — a critical consideration for position sizing, and one that explains why the stock has fallen so much harder than the index during this risk-off period. The short ratio of 3.41 is moderate and does not yet signal an imminent squeeze, but it bears watching if the stock stabilizes near $500.
Beta
1.54
1.54x market volatility
Max Drawdown
-34.2%
Largest decline past year
52-Week Range
$501-$770
Price range past year
Annual Return
-20.5%
Cumulative gain past year
| Period | IDXX Return | S&P 500 |
|---|---|---|
| 1m | -7.5% | -2.0% |
| 3m | -11.1% | +1.4% |
| 6m | -11.7% | +15.0% |
| 1y | -20.5% | +15.7% |
| ytd | -23.9% | +11.6% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
IDXX Fundamental Analysis
IDEXX's revenue trajectory remains healthy even as the stock collapses: Q1 2026 revenue of $1.141 billion grew 14.26% year-over-year versus Q1 2025's $998.4 million, an acceleration from the prior-year comparison and the strongest recent print. The multi-quarter trend is constructive — revenue rose from $1.091 billion in Q4 2025 to $1.105 billion in Q3 2025 to $1.141 billion in Q1 2026 — and the segment mix shows Product revenue of $666.1 million alongside Service revenue of $474.7 million, with the consumables-and-services model providing recurring, high-margin revenue that underpins the growth algorithm. The 14.26% YoY growth, combined with management's raised guidance on higher clinical visits and diagnostic frequency, suggests the fundamental demand backdrop is intact and that the share price decline is a multiple-compression story rather than a fundamental deterioration story. Profitability is exceptional: Q1 2026 net income was $278.4 million on a 24.41% net margin, with a gross margin of 63.35% and an operating margin of 31.78%, and the trend is one of margin expansion — gross margin improved from 60.35% in Q4 2025 and 61.83% in Q3 2025 to 63.35% in Q1 2026, while net margin rose from 22.76% to 24.41% over the same span. EBITDA of $400.9 million in Q1 2026 (35.14% EBITDA margin) versus $356.2 million in Q4 2025 confirms operating leverage is working, and the 24.62% net margin and 31.60% operating margin reported in the valuation data are well above typical diagnostics-industry levels, reflecting pricing power and the consumables annuity. The balance sheet is solid: debt-to-equity of 0.671 is conservative, the current ratio of 1.167 provides adequate near-term liquidity, and ROE of 65.99% (with ROA of 27.09%) is extraordinarily high, though the elevated ROE is partly a function of the company's aggressive share repurchases reducing the equity base. Free cash flow remains robust at $1.08 billion TTM, with Q1 2026 free cash flow of $234.3 million on operating cash flow of $266.2 million, and the company returned capital aggressively via $351.0 million of stock repurchased in Q1 2026 alone — a signal of confidence in intrinsic value. The main caveat is the cash conversion cycle, which has stretched to roughly 109-115 days on inventory days of 78-83 and DSO of 55-57, and the cash flow to debt ratio of 0.24 is modest, but with interest coverage of 46.8x, the financial risk profile remains low.
Quarterly Revenue
$1.1B
2026-03
Revenue YoY Growth
+14.3%
YoY Comparison
Gross Margin
63.3%
Latest Quarter
Free Cash Flow
$1.1B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is IDXX Overvalued?
Because IDEXX is solidly profitable — Q1 2026 net income of $278.4 million and trailing EPS of $3.48 — the PE ratio is the appropriate primary metric, and the stock trades at a trailing PE of 51.37x versus a forward PE of 30.15x. The enormous gap between trailing and forward multiples implies the market expects a dramatic earnings step-up, consistent with the analyst consensus EPS estimate of $25.62 for the forward period versus the current run-rate, and it means the stock is far cheaper on forward earnings than the headline trailing number suggests. The PEG ratio of 2.31 indicates that even after the derating, investors are paying a meaningful premium for growth, so the forward multiple is only attractive if that growth materializes. On peer comparison, IDEXX's trailing PE of 51.37x and PS ratio of 12.59x sit at a premium to broad healthcare and diagnostics averages, though the data does not provide a specific industry average for direct comparison; the EV/EBITDA of 37.50x and P/B of 33.75x are unambiguously rich on an absolute basis, reflecting the market's willingness to pay up for the company's 63% gross margin and 24.6% net margin versus the lower-margin profile of many diagnostics peers. The premium is defensible on quality grounds — ROE of 66%, ROA of 27%, and a consumables-driven recurring revenue model — but it leaves little room for error, and the 2.31 PEG suggests the growth premium is still substantial. Historically, IDEXX's PE has compressed dramatically: it traded at 40.37x in Q1 2026, 54.56x in Q4 2025, and as high as 85.74x in Q4 2021, while the PS ratio has fallen from 69.72x in Q4 2021 to 12.59x today — a roughly 82% compression in the sales multiple. The current PE of 51.37x is near the lower end of the stock's multi-year band (versus 85.7x in late 2021 and 59.3x in Q4 2023), and the PS ratio of 12.59x is at a multi-year trough, which suggests the market has already priced in a significant slowdown. The key question is whether this represents a genuine value opportunity created by indiscriminate selling or a rational repricing of a business whose growth is structurally decelerating — the forward PE of 30.15x leans toward the former, but the persistent negative relative strength leans toward the latter.
PE
51.4x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 35x~75x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
37.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks center on the company's dependence on continued growth to justify its valuation. While debt-to-equity of 0.671 is conservative and interest coverage of 46.8x is strong, the cash conversion cycle has stretched to roughly 109-115 days on inventory days of 78-83 and DSO of 55-57, and the cash flow to debt ratio of 0.24 is modest. The current ratio of 1.167 provides only adequate near-term liquidity. More importantly, the trailing PE of 51.37x and EV/EBITDA of 37.50x leave no room for error: any deceleration in the 14.26% revenue growth rate or compression in the 63.35% gross margin would likely trigger a violent multiple reset. The company's roughly 35% international revenue exposure also introduces currency and geopolitical risk that could pressure reported results.
Market and competitive risks are elevated given the stock's beta of 1.538, meaning IDEXX is roughly 54% more volatile than the market, so a 10% SPY drawdown could translate to a 15%+ move in IDXX. The stock has already fallen -21.77% over one year versus the S&P 500's +16.22% gain, a -37.99% relative underperformance that confirms persistent institutional distribution. Valuation compression risk remains significant: while the PS ratio has fallen from 69.72x in Q4 2021 to 12.59x today, the PEG ratio of 2.31 still embeds a substantial growth premium. Competitive disruption from lower-cost diagnostic alternatives or vertical integration by large veterinary consolidators could erode IDEXX's pricing power. The recent news of raised guidance on higher clinical visits is a positive, but it also raises the bar for future quarters.
In a worst-case scenario, a combination of decelerating U.S. veterinary clinic visit growth, further multiple compression, and a broad market risk-off event could drive the stock below its 52-week low of $500.61. The analyst low target of $470.00 represents a -6.9% decline from the current price of $504.70, while a retest of the maximum drawdown of -34.17% from the 52-week high would imply a price near $507, which is roughly current levels. A more severe scenario, such as a recession that curtails discretionary pet healthcare spending, could push the stock toward $450-$470, representing a -7% to -11% decline from current levels. The short ratio of 3.41 is moderate and does not yet signal an imminent squeeze, but it bears watching if the stock stabilizes near $500.
FAQ
The most severe risk is valuation compression: with a trailing PE of 51.37x and EV/EBITDA of 37.50x, any deceleration in the 14.26% revenue growth rate could trigger a violent multiple reset. Second, the stock's beta of 1.538 means it is roughly 54% more volatile than the market, so a 10% SPY drawdown could translate to a 15%+ decline in IDXX. Third, competitive and structural risks include potential disruption from lower-cost diagnostic alternatives or vertical integration by large veterinary consolidators, which could erode IDEXX's pricing power. Fourth, the cash conversion cycle has stretched to roughly 109-115 days, and the cash flow to debt ratio of 0.24 is modest, though interest coverage of 46.8x mitigates immediate financial risk. Ranked by severity, valuation compression and macro sensitivity are the most immediate threats, followed by competitive disruption and operational efficiency.
The 12-month forecast is divided into three scenarios. The base case (50% probability) targets $600-$700, assuming revenue growth remains in the 12-14% range and the forward PE stabilizes around 25-30x on the $25.62 EPS estimate. The bull case (30% probability) targets $700-$805, requiring Q2 and Q3 2026 earnings beats, stabilization in veterinary clinic visit growth, and multiple expansion back toward historical norms. The bear case (20% probability) targets $450-$500, driven by revenue growth decelerating below 10%, downward EPS revisions, and a decisive break below the 52-week low of $500.61. The most likely scenario is the base case, with the key assumption being that IDEXX continues to execute fundamentally while the market gradually regains confidence in the veterinary diagnostics growth story.
IDXX presents a mixed valuation picture depending on the metric used. On a forward basis, the PE of 30.15x is near the lower end of the stock's multi-year band (versus 85.74x in Q4 2021 and 59.3x in Q4 2023), suggesting the stock is undervalued relative to its own history. The PS ratio of 12.59x has compressed roughly 82% from 69.72x in Q4 2021, also near a multi-year trough. However, on absolute metrics, the EV/EBITDA of 37.50x and P/B of 33.75x remain rich, and the PEG ratio of 2.31 indicates investors are still paying a premium for growth. The market appears to be pricing in a significant slowdown, and the forward PE of 30.15x implies the market expects the $25.62 EPS estimate to be achieved. If that growth materializes, the stock is undervalued; if it disappoints, further compression is likely.
From a risk/reward perspective, IDXX offers a compelling long-term opportunity but carries significant near-term risk. The stock trades at $504.70, just 1.5% above its 52-week low of $500.61, with analyst targets implying +38.5% upside to the average of $698.92. However, the -37.99% relative underperformance versus SPY over one year and accelerating downside momentum suggest the market is pricing in material deterioration. The biggest downside risk is a break below $500, which could drive the stock toward the analyst low target of $470. For long-term investors with a 3-5 year horizon who believe in the veterinary diagnostics growth story, the current valuation (forward PE of 30.15x) may represent an attractive entry point, but near-term traders should wait for stabilization above $520 before committing capital.
IDXX is best suited for long-term investment with a minimum holding period of 3-5 years. The company is in a mature growth stage with a dominant market position, 14.26% revenue growth, and a consumables-driven recurring revenue model that provides earnings visibility. The beta of 1.538 and the current -34.17% maximum drawdown indicate high volatility, making it unsuitable for short-term trading unless one is actively trading the technical setup around the $500 support level. The absence of a dividend (payout ratio of 0%) means total return depends entirely on capital appreciation, which favors a long-term horizon. Short-term traders could look for a bounce off the 52-week low of $500.61, but the persistent negative relative strength and accelerating downside momentum make this a high-risk proposition. For long-term investors, the forward PE of 30.15x and the analyst average target of $698.92 offer a favorable risk/reward if the fundamental growth trajectory remains intact.
